331 related articles for article (PubMed ID: 33299175)
1. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
[TBL] [Abstract][Full Text] [Related]
2. The structure of the catalytic domain of the ATP synthase from
Zhang AT; Montgomery MG; Leslie AGW; Cook GM; Walker JE
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4206-4211. PubMed ID: 30683723
[TBL] [Abstract][Full Text] [Related]
3. The ATP synthase inhibitor bedaquiline interferes with small-molecule efflux in Mycobacterium smegmatis.
Lu P; Villellas C; Koul A; Andries K; Lill H; Bald D
J Antibiot (Tokyo); 2014 Dec; 67(12):835-7. PubMed ID: 24916895
[No Abstract] [Full Text] [Related]
4. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.
Courbon GM; Palme PR; Mann L; Richter A; Imming P; Rubinstein JL
EMBO J; 2023 Aug; 42(15):e113687. PubMed ID: 37377118
[TBL] [Abstract][Full Text] [Related]
5. Diarylquinolines target subunit c of mycobacterial ATP synthase.
Koul A; Dendouga N; Vergauwen K; Molenberghs B; Vranckx L; Willebrords R; Ristic Z; Lill H; Dorange I; Guillemont J; Bald D; Andries K
Nat Chem Biol; 2007 Jun; 3(6):323-4. PubMed ID: 17496888
[TBL] [Abstract][Full Text] [Related]
6. Structure of the ATP synthase from
Montgomery MG; Petri J; Spikes TE; Walker JE
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34782468
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State.
Patil V; Jain V
J Bacteriol; 2019 Oct; 201(19):. PubMed ID: 31285242
[No Abstract] [Full Text] [Related]
8. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.
Segala E; Sougakoff W; Nevejans-Chauffour A; Jarlier V; Petrella S
Antimicrob Agents Chemother; 2012 May; 56(5):2326-34. PubMed ID: 22354303
[TBL] [Abstract][Full Text] [Related]
9. ATP Synthase, an Emerging Target in TB Drug Discovery: Review of SAR and Clinical Pharmacology of Diarylquinoline Inhibitors.
Dhulap A; Banerjee P
Curr Drug Targets; 2021; 22(11):1207-1221. PubMed ID: 33480344
[TBL] [Abstract][Full Text] [Related]
10. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Salifu EY; Agoni C; Olotu FA; Soliman MES
Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
[TBL] [Abstract][Full Text] [Related]
11. Variations of the Mycobacterium abscessus F-ATP synthase subunit a-c interface alter binding and potency of the anti-TB drug bedaquiline.
Krah A; Ragunathan P; Bond PJ; Grüber G
Biochem Biophys Res Commun; 2024 Jan; 690():149249. PubMed ID: 38000294
[TBL] [Abstract][Full Text] [Related]
12. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
Saxena AK; Alam M
Curr Top Med Chem; 2020; 20(29):2723-2734. PubMed ID: 32885753
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
14. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase.
Kundu S; Biukovic G; Grüber G; Dick T
Antimicrob Agents Chemother; 2016 Nov; 60(11):6977-6979. PubMed ID: 27620476
[TBL] [Abstract][Full Text] [Related]
16. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
[TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.
Haagsma AC; Podasca I; Koul A; Andries K; Guillemont J; Lill H; Bald D
PLoS One; 2011; 6(8):e23575. PubMed ID: 21858172
[TBL] [Abstract][Full Text] [Related]
19. Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds.
He C; Preiss L; Wang B; Fu L; Wen H; Zhang X; Cui H; Meier T; Yin D
ChemMedChem; 2017 Jan; 12(2):106-119. PubMed ID: 27792278
[TBL] [Abstract][Full Text] [Related]
20. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
